ATE361096T1 - Antikörper zur modulierung der upa/upar interaktion und deren verwendungen - Google Patents

Antikörper zur modulierung der upa/upar interaktion und deren verwendungen

Info

Publication number
ATE361096T1
ATE361096T1 AT02710810T AT02710810T ATE361096T1 AT E361096 T1 ATE361096 T1 AT E361096T1 AT 02710810 T AT02710810 T AT 02710810T AT 02710810 T AT02710810 T AT 02710810T AT E361096 T1 ATE361096 T1 AT E361096T1
Authority
AT
Austria
Prior art keywords
upar
upa
modulating
antibodies
interaction
Prior art date
Application number
AT02710810T
Other languages
English (en)
Inventor
Francesco Blasi
Nicolai Sidenius
Massimo Resnati
Anna Mondino
Guido Poli
Massimo Alfano
Original Assignee
San Raffaele Centro Fond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by San Raffaele Centro Fond filed Critical San Raffaele Centro Fond
Application granted granted Critical
Publication of ATE361096T1 publication Critical patent/ATE361096T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
AT02710810T 2001-01-25 2002-01-22 Antikörper zur modulierung der upa/upar interaktion und deren verwendungen ATE361096T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26319801P 2001-01-25 2001-01-25

Publications (1)

Publication Number Publication Date
ATE361096T1 true ATE361096T1 (de) 2007-05-15

Family

ID=23000794

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02710810T ATE361096T1 (de) 2001-01-25 2002-01-22 Antikörper zur modulierung der upa/upar interaktion und deren verwendungen

Country Status (7)

Country Link
US (2) US7737256B2 (de)
EP (1) EP1365797B1 (de)
AT (1) ATE361096T1 (de)
AU (1) AU2002229721A1 (de)
DE (1) DE60219888T2 (de)
ES (1) ES2282397T3 (de)
WO (1) WO2002058714A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074891B2 (en) * 2003-02-07 2006-07-11 Posco Leukocyte stimulating peptides
EP1853624A2 (de) * 2005-01-31 2007-11-14 Fondazione Centro San Raffaele Del Monte Tabor Von urokinaseplasminogenaktivatorrezeptor abgeleitete therapeutische peptide
US7951589B2 (en) 2005-03-11 2011-05-31 Wilex Ag Monoclonal antibodies specific for the chemotactic epitope of the urokinase-type plasminogen activator receptor
ITMI20061607A1 (it) * 2006-08-09 2008-02-10 Maria Vincenza Carriero Peptidi con attivita farmacologica
DK2117571T3 (en) 2006-12-08 2017-05-08 Monopar Therapeutics Inc Urokinase-type plasminogen activator receptor epitope
US8815519B2 (en) 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases
WO2008104857A2 (en) * 2007-02-26 2008-09-04 Universite De Lausanne Method for predicting susceptibility of hiv infection
CA2919687A1 (en) * 2013-08-01 2015-02-05 The General Hospital Corporation Non-glycosylated supar biomarkers and uses thereof
EP3856244A4 (de) * 2018-09-28 2022-07-20 Jochen Reiser Supar sowie vorhersage und behandlung von akuter nierenläsion
CN113975381A (zh) * 2020-07-26 2022-01-28 刘建宁 尿激酶原及其变体在病毒引起的凝血疾病中的应用
EP4610269A1 (de) 2024-02-29 2025-09-03 3B Pharmaceuticals GmbH Urokinase plasminogen aktivator surface rezeptor (upar) liganden zur diagnostischen oder therapeutischen verwendung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU652917B2 (en) * 1989-04-07 1994-09-15 Cancerforskningsfondet Af 1989 Urokinase-type plasminogen activator receptor
JP2852192B2 (ja) 1994-07-08 1999-01-27 カンセアフォースクニングスフォンデン・アフ・１９８９（フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンセアフォースクニング） ｕＰＡＲのドメイン２＋３のｕＰＡ結合部位および抗体
WO1996013160A1 (en) 1994-11-01 1996-05-09 New England Deaconess Hospital Use of urokinase-type plasminogen activators to inhibit hiv infectivity
US6462170B1 (en) * 1997-03-20 2002-10-08 Fondazione Centro San Raffaele Del Monte Tabor UPAR mimicking peptide
US6077508A (en) * 1998-03-23 2000-06-20 American Diagnostica Inc. Urokinase plasminogen activator receptor as a target for diagnosis of metastases
US6902884B1 (en) 1999-11-25 2005-06-07 Virogates Aps Method and tool for prognosticating HIV infection in a subject by measuring soluble urokinase plasminogen activator receptor, degradation products thereof, and urokinase plasminogen activator receptor

Also Published As

Publication number Publication date
WO2002058714A2 (en) 2002-08-01
US7737256B2 (en) 2010-06-15
AU2002229721A1 (en) 2002-08-06
DE60219888T2 (de) 2008-01-17
WO2002058714A3 (en) 2002-10-24
EP1365797A2 (de) 2003-12-03
DE60219888D1 (de) 2007-06-14
ES2282397T3 (es) 2007-10-16
EP1365797B1 (de) 2007-05-02
US20040115190A1 (en) 2004-06-17
US20110027285A1 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
ATE385806T1 (de) Fusionsproteine
BR0111125A (pt) Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos
DK0804236T3 (da) Anvendelse af anti-TNF-antistoffer som lægemidler til behandling af sygdomme, som involverer forhøjede interleukin-6-serumniveauer
EP1688488A4 (de) Biospezifischer antikörper als ersatz für funktionelle proteine
CO5690537A2 (es) Formas solidas de anticuerpos anti-egfr
CY1118991T1 (el) Φαρμακοτεχνικη μορφη ανθρωπινων αντισωματων για θεραπεια σχετικων με tnf-αλφα διαταραχων
ATE361096T1 (de) Antikörper zur modulierung der upa/upar interaktion und deren verwendungen
BR0011838B1 (pt) elemento de sela e estrutura de misturador estático.
DE60118544D1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
DK1287364T3 (da) Diagnostisk og terapi til makulære degenerationsrelaterede lidelser
EP1505990A4 (de) Verfahren zur behandlung von hepatitis
CY1112621T1 (el) Clostridia νευροτοξινης για χρηση στη θεραπεια της ρινικης συμφορησης
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ATE431405T1 (de) Tnf-rezeptor-ähnliche moleküle und deren anwendungen
DE69534551D1 (de) Neue methode zum auffindenund bewerten biologisch aktiver moleküle
UY27841A1 (es) Amidas de ácidos 2-heteroarilcarboxílicos
SE0102147D0 (sv) New methods
ATE416756T1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
WO2022235551A3 (en) Fc-fusion protein therapeutic for the treatment of pancreatitis
NO20054631L (no) Antistoff mot tumorspesifikt antigen som mal
ATE210460T1 (de) Zusammensetzungen, welche adp-ribosyltransferase- aktivität aufweisen und methoden für ihre herstellung und die verwendung derselben
DE59611293D1 (de) Protein mit dnase-aktivität
DE60020970D1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen
CY1110278T1 (el) Μεθοδος διαλογης παραγοντων ικανων να θεραπευουν την παχυσαρκια
DE69521281D1 (de) Verfahren zur Herstellung von menschlichem oder humanem Matrilysin mittels rekombinanter DNA.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1365797

Country of ref document: EP